Protachykinin-1

experimental

Also known as: PPT, TAC1, P20366

**Mechanism of Action** Protachykinin-1 (PPT, TAC1) is the precursor protein encoded by the *TAC1* gene, which is proteolytically processed into multiple tachykinin peptides, including substance P, neurokinin A, neurokinin B, and neuropeptide K. These peptides act primarily through G protein-coupled receptors (NK1R, NK2R, NK3R) to modulate neuronal excitability, pain transmission, and neurogenic inflammation. Tachykinins induce vasodilation, smooth muscle contraction (e.g., in respiratory and gastrointestinal tracts), and stimulate secretion from exocrine glands. Their effects are mediated via calcium-dependent signaling pathways and release of secondary messengers. **Key Research Findings** Preclinical studies demonstrate that PPT-derived tachykinins are critical mediators of nociception, stress responses, and neuroimmune interactions. Elevated PPT expression is observed in inflammatory and pain models, with antagonists of NK1R (e.g., aprepitant) showing analgesic and antiemetic effects in animal studies. PPT knockout mice exhibit reduced pain sensitivity and impaired neurogenic inflammation. Emerging research links PPT polymorphisms to susceptibility in migraine, irritable bowel syndrome, and psychiatric disorders, though human data remain limited. **Clinical Relevance** PPT and its peptide products are experimental targets for chronic pain, chemotherapy-induced nausea, and inflammatory diseases. NK1R antagonists are approved for emesis, but direct PPT modulation has not reached clinical trials. Further research is needed to validate PPT as a therapeutic target, particularly in conditions with dysregulated tachykinin signaling. For research purposes only — not medical advice.

Key data

Category
Cognitive & Neuroprotective
Sequence
MKILVALAVFFLVSTQLFAEEIGANDDLNYWSDWYDSDQIKEELPEPFEHLLQRIARRPKPQQFFGLMGKRDADSSIEKQVALLKALYGHGQISHKRHKTDSFVGLMGKRALNSVAYERSAMQNYERRR
Molecular weight
386.4 g/mol
Molecular formula
C24H22N2O3
CAS number
263717-53-9
Research status
experimental
References
15
Tags
uniprot, 3d-structure, alternative-splicing, amidation, cleavage-on-pair-of-basic-residues, direct-protein-sequencing, neuropeptide, neurotransmitter, proteomics-identification, reference-proteome, secreted, signal

Mechanism of action

Tachykinins are active peptides which excite neurons, evoke behavioral responses, are potent vasodilators and secretagogues, and contract (directly or indirectly) many smooth muscles

Research & studies

Interrogation of the human cortical peptidome uncovers cell-type specific signatures of cognitive resilience against Alzheimer's disease
Scientific reports · 2024 · PubMed
Tumor necrosis factor mediates the impact of PM(2.5) on bone mineral density: Inflammatory proteome Mendelian randomization and colocalization analyses
Ecotoxicology and environmental safety · 2024 · PubMed
Effect of Fish Stock Density on Hormone Genes Expression from Brain and Gastrointestinal Tract of Salmo salar
Animals : an open access journal from MDPI · 2022 · PubMed
Quantitative Characterization of the Neuropeptide Level Changes in Dorsal Horn and Dorsal Root Ganglia Regions of the Murine Itch Models
Journal of proteome research · 2020 · PubMed
Neuropeptide imaging in rat spinal cord with MALDI-TOF MS: Method development for the application in pain-related disease studies
European journal of mass spectrometry (Chichester, England) · 2017 · PubMed
Tachykinins Processing is Significantly Impaired in PC1 and PC2 Mutant Mouse Spinal Cord S9 Fractions
Neurochemical research · 2015 · PubMed

PC1 and PC2 mediate the formation of substance P and Tachykinin 58-71 from protachykinin peptides.; Mutant PC1 and PC2 mouse spinal cord fractions showed over 50% reduction in the rate of formation of these peptides.; Both PC1 and PC2 are involved in C-terminal processing of protachykinin peptides.; The findings suggest a major role for PC1 and PC2 in the maturation of protachykinin-1 protein.

Nasal allergen deposition leads to conjunctival mast cell degranulation in allergic rhinoconjunctivitis
American journal of rhinology & allergy · 2014 · PubMed
Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and l-DOPA-induced dyskinesia
Neurobiology of disease · 2014 · PubMed

Frequently asked questions

What is Protachykinin-1?

**Mechanism of Action** Protachykinin-1 (PPT, TAC1) is the precursor protein encoded by the *TAC1* gene, which is proteolytically processed into multiple tachykinin peptides, including substance P, neurokinin A, neurokinin B, and neuropeptide K. These peptides act primarily through G protein-coupled receptors (NK1R, NK

How does Protachykinin-1 work?

Tachykinins are active peptides which excite neurons, evoke behavioral responses, are potent vasodilators and secretagogues, and contract (directly or indirectly) many smooth muscles

What is the research status of Protachykinin-1?

Protachykinin-1 is currently classified as experimental, with 15 research references on record. This is for research purposes only and is not medical advice.

What is the molecular weight of Protachykinin-1?

Protachykinin-1 has a molecular weight of approximately 386.4 g/mol (formula C24H22N2O3).

Related peptides

Build on Protachykinin-1 data programmatically

Structured peptide data, semantic search, and AI summaries via one API.

Get a free API key